Cellectis (CLLS) released its monthly information on share capital and voting rights under Article 223-16 of the French financial markets authority rules.
As of June 30, 2026, Cellectis reported 100,698,158 shares outstanding and a total of 105,551,650 voting rights on Euronext Growth.
The update confirming 100,698,158 shares and 105,551,650 voting rights mainly refreshes capital-stru...
Analysis
The update confirming 100,698,158 shares and 105,551,650 voting rights mainly refreshes capital-structure transparency. With an effective F‑3 shelf and low reported short positioning, investors may watch how any future issuances alter this balance.
Key Figures
Total shares outstanding:100,698,158 sharesTotal voting rights:105,551,650 voting rightsShare price (pre-headline):$3.30+1 more
4 metrics
Total shares outstanding100,698,158 sharesAs of June 30, 2026 on Euronext Growth
Total voting rights105,551,650 voting rightsAs of June 30, 2026 on Euronext Growth
Share price (pre-headline)$3.30Nasdaq, around publication time
Market capitalization$301,834,443Pre-headline market value
Announced date, time and location of June 25, 2026 annual meeting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news has mostly seen Cellectis’ share price move in the same direction as the perceived news tone, with only one notable divergence on positive clinical data.
Regulatory & Risk Context
Active S-3 Shelf · Short Interest: 0.51%
Shelf Active
Short Interest
0.51% of float
0%15%30%+
lowas of 2026-06-15Days to cover: 6.3
Reported short interest is low, suggesting limited short-squeeze potential and that short covering alone is unlikely to be a major driver of price volatility.
Active S-3 Shelf Registration
2025-07-02
An effective F-3 shelf registration dated 2025-07-02 gives the company pre-cleared capacity to issue securities through 2028-07-02, which could be used for future financing transactions.
An ISIN code is a unique identifier for a specific financial asset, like a stock or bond, similar to a product's barcode. It helps investors, traders, and banks quickly and accurately find and track that asset across different markets worldwide. This makes buying, selling, and managing investments more organized and reliable.
voting rightsfinancial
"Total number of voting rights"
Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.
share capitalfinancial
"Total number of shares in the capital"
Share capital is the total amount of money a company raises by selling pieces of itself, called shares, to investors. It’s like a company’s savings from many owners, which helps fund its growth and operations. This money matters because it shows how much the company has raised from shareholders and how it’s financed its business.
Euronext Growth is a stock market for smaller, emerging companies that want to raise money and grow. It makes it easier for these companies to get listed and attract investors, similar to a training ground for future big businesses. This helps new companies develop and eventually become larger, more established firms.
How many Cellectis (CLLS) shares were outstanding on June 30, 2026?
On June 30, 2026, Cellectis reported 100,698,158 shares outstanding. According to Cellectis, this figure represents the total number of shares in its share capital listed on Euronext Growth at that month-end reporting date.
What was the total number of Cellectis (CLLS) voting rights as of June 30, 2026?
As of June 30, 2026, Cellectis reported 105,551,650 total voting rights. According to Cellectis, this voting-rights figure accompanies 100,698,158 shares outstanding on Euronext Growth, providing investors with updated governance and capital structure information.
On which market is Cellectis (CLLS) share capital and voting rights reported for June 30, 2026?
Cellectis reports its June 30, 2026 share capital and voting rights on Euronext Growth. According to Cellectis, the company provides this monthly disclosure in line with Article 223-16 of the French financial markets authority’s General Regulation.
Why does Cellectis (CLLS) publish monthly information on share capital and voting rights?
Cellectis publishes monthly share capital and voting-rights data to keep investors informed about its capital structure. According to Cellectis, this reporting follows Article 223-16 requirements from the French financial markets authority, enhancing transparency for Euronext Growth shareholders.
What identification code is used for Cellectis (CLLS) in the June 30, 2026 disclosure?
The June 30, 2026 disclosure identifies Cellectis with ISIN code FR0010425595. According to Cellectis, this ISIN uniquely labels its shares traded on Euronext Growth, helping investors and intermediaries track the company’s securities and related voting-rights information.
